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A B S T R A C T
Drug-eluting Embolic Bead - Transarterial Chemoembolisation (DEB-TACE) is a minimally invasive embolising
treatment for liver tumours that allows local release of chemotherapeutic drugs via ion exchange, following
delivery into hepatic arterial vasculature. Thus far, no single in vitro model has been able to accurately predict
the complete kinetics of drug release from DEB, due to heterogeneity of rate-controlling mechanisms throughout
the process of DEB delivery. In this study, we describe two in vitro models capable of distinguishing between
early phase and late phase drug release by mimicking in vivo features of each phase. First, a vascular ﬂow system
(VFS) was used to simulate the early phase by delivering DEB into a silicon vascular cast under high pulsatile
ﬂow. This yielded a burst release proﬁle of drugs from DEB which related to the dose adjusted Cmax observed in
pharmacokinetic plasma proﬁles from a preclinical swine model. Second, an open loop ﬂow-through cell system
was used to model late phase drug release by packing beads in a column with an ultra-low ﬂow rate. DEB loaded
with doxorubicin, irinotecan and vandetanib showed diﬀerential drug release rates due to their varying chemical
properties and unique drug-bead interactions. Using more representative in vitro models to map discrete phases
of DEB drug release will provide a better capability to predict the pharmacokinetics of developmental for-
mulations, which has implications for treatment safety and eﬃcacy.
1. Introduction
Drug-Eluting embolization Beads (DEBs) have been developed pri-
marily for the locoregional treatment of malignancies in the liver by
means of minimally invasive delivery through Trans-arterial
Chemoembolisation (TACE) (Nicolini et al., 2011). There are now
several commercially-available devices on the market that are all gen-
erally composed of hydrogel microspheres of calibrated sizes that are
capable of interacting with certain drugs by an ion-exchange process
(Facciorusso, 2018; de Baere et al., 2016). For example, DC Bead™ are
composed of a polyvinyl alcohol (PVA) hydrogel modiﬁed to contain
negatively charged sulfonate groups, enabling ionic interaction with
positively charged drugs which is reversible in ion-rich environments
such as blood (Lewis, 2009). These devices are supplied to the hospital
pharmacy where they are loaded with the appropriate chemother-
apeutic drug and then supplied to the physician for administration
using X-ray guided navigation through the blood vessels into the liver in
order to target the site of the tumour. The choice of drug is dependent
upon the type of liver tumour being treated and the physician's pre-
ference. For the treatment of hepatocellular carcinoma (HCC, primary
liver cancer) (Lammer et al., 2010) or certain tumours that have spread
to the liver such as breast cancer metastases (Martin et al., 2012), the
most common agent selected is doxorubicin hydrochloride at a dose of
25 or 37.5 mg/mL of hydrated beads, but in some instances structurally
similar anthracycline drugs such as epirubicin (Nicolini et al., 2010) or
idarubicin (Boulin et al., 2014) have been used as alternatives. On the
other hand, metastatic colorectal cancer (mCRC) to the liver has been
treated with DEBs loaded with irinotecan hydrochloride using a slightly
modiﬁed administration technique (Martin et al., 2009, 2011; Taylor
et al., 2007). Most recently there has been much interest in the delivery
of other more targeted therapeutic agents from DEBs, in particular the
multi-tyrosine kinase inhibitors (MTKi) which have inhibitory eﬀects
on tumour microvasculature (Fuchs et al., 2014; Hagan et al., 2017;
Lahti et al., 2015). Indeed, the ﬁrst HCC patients have recently been
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treated in a clinical trial where the MTKi vandetanib has been pre-
loaded onto a DEB, in this case a newer device platform which is also
radiopaque in nature and therefore can be visualized intra and post-
procedurally using X-ray based imaging methods (Ashraﬁ et al., 2017;
Duran et al., 2016; ClinicalTrials.gov, 2017).
As interest in DEB-mediated local delivery of diﬀerent chemother-
apeutic drugs grows, there is a need to be able to screen these agents
using in vitro methodologies that provide some level of prediction as to
how the drug may be released in vivo. There have been many diﬀerent
types of elution test described for the evaluation of DEBs, including
simple USP Type II apparatus studies which are suited for Quality
Control tests to ensure uniformity between batches, but are unin-
formative on how the products will release drug once placed within a
blood vessel (Gonzalez et al., 2008). USP Type IV and T-cell Apparatus
have been shown to be more predictive of the in vivo situation, as they
allow for elements of drug diﬀusion and convection (Gonzalez et al.,
2008; Amyot et al., 2002; Fuchs et al., 2015; Jordan et al., 2010). As
drug elutes from the beads and travels through the embolised vessel
walls into tissue, the drug's physicochemical properties will dictate how
it diﬀuses and interacts with cells or is eventually carried away as it
enters more distant vessels in which blood ﬂow is maintained. Elements
of drug metabolism however, cannot be easily accommodated in these
models. More recently, we have described an open-loop ﬂow through
system which under the right conditions can be representative of the
long-term release that has been observed for doxorubicin in explanted
tissues (Swaine et al., 2016). None of these methods however, are
particularly applicable to the initial 24 h post-delivery of the beads,
where the peak plasma concentrations (Cmax) can be a predictor of the
levels of systemic toxicity that might be experienced by the patient
(Song & Kim, 2017; Lencioni, 2012).
The reason for this lack of correlation is because established in vitro
tests usually begin with a “pre-occluded system” in which the beads
have already been placed into a situation that represents a post-ad-
ministration occlusive mass (Caine et al., 2017a). In order to properly
evaluate how a DEB will respond to delivery in vivo, the administration
phase must also be mimicked as per the schematic in Fig. 1. The beads
must be mixed with contrast agent before delivery, which, depending
on the ionic composition of the contrast agent, can induce in itself a
small degree of drug elution from the surface layers of the beads. The
bead/contrast suspension is then slowly delivered in small “puﬀs” at a
rate of around 1mL of suspension per minute in order that the beads are
carried by the blood into the arterial high ﬂow areas (normally the
tumour when it is hypervascular in nature) and distribute into the distal
arterioles without premature proximal blockage (phase 1, the initial
15–30min during bead delivery). If the drug-bead interaction is weak,
caused for example by steric hindrance and/or charge delocalisation at
the drug binding site (Biondi et al., 2013), there may be a burst of drug
release during this phase as the beads are surrounded by ion-rich blood
which is an eﬀective medium for the sequestration of drug (Jordan
et al., 2010; Taylor et al., 2007). Beads will ﬁll vessels distally and
compact until they form a cast within the vessel architecture and ﬂow
between and around the beads is slowed to near stasis (phase 2, which
starts to occur whilst the beads are still being delivered but would re-
present the next 15–30min as the beads redistribute and compact into
the vessels). Finally, the stagnated blood between the beads will
eventually clot to form an occlusive mass, and ions from the sur-
rounding tissues will diﬀuse into the mass and exchange for the drug
bound to the bead reservoirs, leaving the drug to diﬀuse into the sur-
rounding tissues by mass transfer (phase 3, which starts to occur once
the beads have formed an occlusive mass and can continue for days to
weeks depending upon the drug and dose delivered).
In this study, we report for the ﬁrst time on a drug elution test
method that mimics the drug release during the DEB administration
procedure (phases 1 and 2 in Fig. 1) and provides a vehicle for a semi-
quantitative prediction of drug plasma exposure over the ﬁrst 24 h post
DEB delivery. The ability to predict this early phase of drug release is of
fundamental importance in the evaluation of these products, as this
dictates the peak plasma levels and hence systemic exposure to the drug
and likelihood of drug-related toxicities. This was achieved by com-
paring the drug elution proﬁles generated using both a custom-built
Vascular Flow System (VFS) and the previously reported open-loop
method, with the pharmacokinetic data obtained from the swine he-
patic artery embolization model. Doxorubicin release from standard
DEB (DC Bead™) was compared to that from a radiopaque DEB (DC
Bead LUMI™), followed by an evaluation of elution of three diﬀerent
drugs loaded onto the radiopaque drug-eluting bead: doxorubicin
(LUMIDOX), irinotecan (LUMIRI) or vandetanib (LUMIVAN). These
drugs were chosen as they have all been used in the clinic for the
treatment of hepatic malignancies.
2. Methods
2.1. Materials
DC Bead™ and DC Bead LUMI™ (both 70–150 μm) were provided by
Biocompatibles UK Ltd. (Farnham, UK). Doxorubicin HCl (Zheijan
Hisun Pharmaceutical Co., China), irinotecan HCl (ScinoPharm,
Taiwan) and vandetanib (> 99% purity, Sanoﬁ Genzyme, UK) were
supplied as powders and dissolved in ultrapure water to the desired
concentration to provide drug loading solutions. Vandetanib solution
was acidiﬁed to pH 4.7 with hydrochloric acid to aid drug solubility.
Non-ionic contrast agent composed of 755mg/mL iohexol
1
2
3
Microcatheter
Hepatic vessel
Drug-eluting
Beads
Fig. 1. Schematic of the phases of DEB delivery.
Phase 1: DEB suspension is injected via the hepatic
artery and exposed to free ﬂowing, ion-rich blood.
Phase 2: DEB begin to embolise distal vessels indu-
cing near stasis of blood ﬂow. Phase 3: DEB establish
clots in tumour vessels and drug is released into
tissue via diﬀusion.
Adapted from (Caine, 2017).
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(Omnipaque™ 350) was purchased from GE healthcare (UK). Phosphate
buﬀered saline (PBS), (pH 7.0, 137mM NaCl) was used as the in vitro
elution medium and was purchased from Source Bioscience
(Nottingham, UK).
2.2. Drug-loading of beads
Beads were loaded with doxorubicin, irinotecan and vandetanib at
37.5 mg, 50mg and 100mg per mL of hydrated beads, respectively.
Speciﬁcally, this involved removal of the saline packing solution with a
pipette to leave an approximate volume of 2mL of bead slurry with
minimal remaining liquid. The appropriate volume/concentration of
drug was added to the vial containing the slurry to achieve the desired
loading and left for a minimum of 1 h for doxorubicin and irinotecan
and 2 h for vandetanib, with occasional agitation.
2.3. Drug-loaded bead characterization and contrast agent compatibility
Optical microscopy was used to investigate morphology of radio-
paque beads post drug loading. DEBs were placed in Petri dishes in a
monolayer and an Olympus BX50 microscope with attached Colorview
III camera was used to capture optical micrographs of each bead
sample. Calibrated sizing software (Stream, Olympus, UK) was used to
measure the diameter of 200 beads per sample.
1 mL of each DEB was suspended in 10mL of neat contrast agent
(Omnipaque 350) by transfer between two syringes via a 3-way con-
nector. To assess drug release into the contrast agent, the suspensions
were stored at room temperature and aliquots of contrast agent were
analysed for drug content over a 24 h period by High Performance
Liquid Chromatography (HPLC) (see Supplementary Information for
method details).
2.4. Early phase elution model: the Vascular Flow System
The Vascular Flow System (VFS) used to study drug elution during
the administration phase was based on the apparatus previously de-
scribed for use in the investigation of the ﬂow dynamics of Y90 mi-
crospheres (Caine et al., 2017b). The system is comprised of a silicon
cast (Elastrat Sarl, Geneva, Switzerland) with circular channel cross-
sections, a 4-mm inlet, and six 0.9-mm outlets (Fig. 2A). In this in-
stance, the VFS, positioned ﬂat on the bench, was circulated with PBS
pre-warmed to 37 °C using a peristaltic pump to induce pulsatile ﬂow of
120mL/min and the circuit modiﬁed as shown in Fig. 2(A). A micro-
catheter (Progreat® 2.4 F, Terumo, Belgium) was steered into a ﬁxed
location beyond the ﬁrst bifurcation point (red arrow, Fig. 2(A)), in
order that two of the six outlet ﬁlters became the target embolization
sites, which were accordingly blocked with a 27 μm mesh (Sefar AG,
Switzerland). The remainder of the outlets, not being exposed to the
DEBs, were recirculated back into the PBS reservoir. DEB/contrast
agent suspensions as prepared in Section 2.3 were then slowly ad-
ministered into the VFS using a syringe pump set at a continuous rate of
1mL/min where upon the beads would exit the microcatheter and
collect in the outlet ﬁlter, producing an occlusive mass and reducing the
eluent ﬂow. The eluent was collected from these outlets, starting from
the initiation of the DEB delivery and every minute for the ﬁrst 10min
then every 5min until a 30minute test period was complete. Drug
concentrations in the eluent at each collection time point were de-
termined using UV spectroscopy (doxorubicin, 483 nm; irinotecan
369 nm) or HPLC (method for vandetanib analysis in supplementary
information) and an elution curve was constructed from the data.
2.5. Mid phase elution model: open loop ﬂow through system
Drug release from radiopaque beads was also proﬁled in a slow rate,
ﬂow through cell open loop system (Fig. 2(B)) as described previously
(Swaine et al., 2016). Drug loaded beads (1mL settled volume) were
sandwiched between two ﬁlter membranes in an elution cell, sub-
merged in a water bath maintained at 37 °C and protected from light.
PBS was pumped through the system at a ﬂow rate of 0.1mL/min, in
order to mimic slow residual blood ﬂow after embolization. Detection
of drug concentration in the eluent over time was performed by auto-
mated UV spectroscopy of eluent passing through a ﬂow through cuv-
ette (doxorubicin, 483 nm; irinotecan, 369 nm; vandetanib, 330 nm).
Drug concentration was calculated from absorbance data using stan-
dards of known concentration for each drug to enable construction of
elution curves.
2.6. Swine hepatic artery embolisation procedure
In order to compare the in vitro elution proﬁles with relevant in vivo
data, pharmacokinetic data was obtained from a pre-clinical study of
transarterial chemoembolization (TACE) using drug-eluting beads in
healthy swine. The embolisation procedure was carried out at MPI
Research (Mattawan, Michigan, USA) using experimentally naïve male
domestic Yorkshire crossbred swine (farm pigs, weights 53.5–66.5 kg at
randomization), as previously described (Denys et al., 2017). The re-
search centre is AAALAC accredited and the study conformed to USDA
Animal Welfare Act (9 CFR parts 1, 2 and 3) and to the ‘Guide for the
Care and Use of Laboratory Animals’, Institute of Laboratory Animal
Resources, National Academy Press, Washington, D.C, 2011.
In brief, each DEB, loaded as described in Section 2.1, was sus-
pended in Omnipaque 350 contrast agent (an iodinated compound in
aqueous solution that is injected into the blood vessels to render the
vessels visible under X-ray imaging). In accordance with their re-
spective instructions for use, DC Bead were suspended in a 50:50 con-
trast agent: saline mixture and DC Bead LUMI were suspended in neat
contrast agent. In both cases the ratio of beads to contrast or diluted
contrast was 1:10. Uniform suspensions were achieved by mixing be-
tween two syringes via 3-way stopcock. The bead suspension was ali-
quoted into a 3mL syringe for delivery through the microcatheter to
allow for better control and re-suspended regularly to prevent sedi-
mentation. Access and selection of the main hepatic artery was
achieved using a 2.7 Fr microcatheter (Progreat®, Terumo Japan). An
arterial branch that fed around 50% of the liver volume was identiﬁed
and an angiogram of the liver lobe(s) taken. With the catheter in po-
sition at the target location, the selected DEB was administered slowly
under continuous ﬂuoroscopy, evaluating changes in vascular ﬂow rate
and appearance of reﬂux or non-target embolization of the beads (in-
ferred from visible contrast ﬂow). The maximum volume was ad-
ministered for all animals (target volume 1mL of sedimented beads).
Dosing occurred in the left lateral lobe or left median lobe for all ani-
mals. After all images were obtained, all guides, catheters, and the
sheath were removed and the femoral artery ligated; the muscle and
subcutaneous tissues were closed with absorbable sutures and the skin
was closed with skin glue.
Blood samples were collected from all animals via the jugular or ear
vein for determination of the plasma concentrations of doxorubicin,
irinotecan, or vandetanib. Samples were collected pre-dose and at se-
lected intervals following administration, up to 14 days. Plasma was
analysed for the concentration of doxorubicin, irinotecan or vandetanib
using validated LC-MS-MS methods speciﬁc to each drug (see supple-
mentary information). Individual doxorubicin, irinotecan, and vande-
tanib plasma concentration-time proﬁles from treated animals were
analysed using model independent methods in Phoenix® WinNonLin®
software (Certara, USA). For each animal, the following plasma phar-
macokinetic parameters were determined: maximum observed plasma
concentration (Cmax), time of maximum observed plasma concentration
(Tmax), and area under the plasma concentration-time curve (AUC). The
AUC from time 0 to 336 h (AUC0–336h), the AUC from time 0 to the time
of the ﬁnal quantiﬁable sample (AUCTlast), and the AUC from time 0 to
inﬁnity (AUCINF) were calculated by the linear trapezoidal method for
all animals with at least three consecutive quantiﬁable concentrations.
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Half-life values (T1/2) were reported for each plasma concentration-
time proﬁles that had suﬃcient plasma concentrations in the terminal
elimination phase (at least three samples not including Tmax) and an
adjusted R2 of ≥0.9.
2.7. In vitro in vivo correlation (IVIVC)
Two approaches for IVIVC were used depending on the elution
model being evaluated. For the early phase VFS model, the eﬀect of
drug elimination was considered less important due to the short dura-
tion (30min) of the experiment. Therefore, a simple point to point
comparison was made between plasma AUC calculated with the tra-
pezoidal method, plotted against % cumulative release in vitro, in order
to assess correlation.
For the later phase ﬂow through elution data, a convolution method
was used to convert in vitro dissolution proﬁle to a predicted plasma
proﬁle using the method described by Qureshi (Qureshi, 2010). The
amount of drug released between time points (amt (mg)) was calculated
and a ﬁrst order elimination model was applied to determine drug
elimination over time. The sum of the drug amount remaining (in mg)
for each time point was then converted to a predicted plasma con-
centration (C) in ng/mL (Eq. (1)).
=
×
×
C amt
V body weight
1000
d (1)
where Vd is the volume of distribution of the drug expressed in L/kg.
Bioavailability was considered to be 100% due to intra-arterial ad-
ministration, therefore was not accounted for in the equation. T1/2 and
Vd for vandetanib and irinotecan in swine were obtained from calcu-
lated values reported in the pre-clinical study reports for LUMIVAN and
Fig. 2. Schematics of in vitro elution models
(Adapted from Caine et al. (2017b)). A) In the vas-
cular ﬂow system, bead suspensions are delivered at
a constant rate via a syringe pump into a silicone
vascular phantom. Mesh inserts at selected channel
ends obstruct the beads forming an occlusion
through which PBS is collected and analysed for
drug content. B) In the ﬂow through cell, beads are
sandwiched between ﬁlter membranes (Adapted
from Swaine et al. (2016)). PBS is pumped at a rate
of 0.1 mL/min through the column to be analysed
for drug content via UV spectroscopy. (For inter-
pretation of the references to colour in this ﬁgure,
the reader is referred to the web version of this ar-
ticle.)
Table 1
Pharmacokinetic parameters obtained from the pre-clinical embolisation studies in healthy swine liver.
DEB Drug dose (mg) Cmax (ng/mL) Cmax/Dose (ng/mL/mg) Tmax (hr) AUCTlast (hr∗ng/mL) AUCTlast/Dose (hr∗ng/mL/
mg)
T½ (hr) Vd (L/kg)
LUMIDOX
n=3
37.5 74.6 ± 27.7 1.99 ± 0.74 0.067 (0.067–0.15) 185 ± 24.6 4.93 ± 0.657 N/Aa N/Aa
LUMIRI
n=3
50 474 ± 138 9.47 ± 2.77 1.067 (0.4–2.2) 2860 ± 278 57.3 ± 5.57 3.67 ± 0.74 1.47 ± 0.42
LUMIVAN
n=8
100 23.8 ± 9.13 0.238 ± 0.09 2 (0.333–4) 535 ± 150 5.35 ± 1.5 22.8 ± 4.15 97.4 ± 26.4
a Parameter could not be calculated due to insuﬃcient plasma-concentration time data.
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Fig. 3. Comparison of doxorubicin elution from non-radiopaque DC Bead and radiopaque DC Bead LUMI (37.5mg/ml). A) Dox elution in the VFS model, B)
percentage dox release in the slow ﬂow through model, C) plasma concentrations of doxorubicin after DEB-TACE procedures in swine for the ﬁrst hour and D) ﬁrst
24 h.
Fig. 4. Optical micrographs of A) LUMIDOX, B) LUMIVAN and C) LUMIRI, scale bars 500 μm. Chemical structures for each drug are shown with protonated amine
groups (site of drug – bead ionic interaction) circled. Physicochemical properties for each drug are listed in the table beneath.
(Source: NIH PubChem open chemistry database)
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LUMIRI (See Table 1). These values were not able to be calculated for
LUMIDOX, therefore T1/2 and Vd for doxorubicin in swine were ob-
tained from the literature, 2.6 h and 4.86 L/kg respectively (Dubbelboer
et al., 2014). Average pig body weights in kg were obtained from the
pre-clinical study reports. AUC of the predicted and actual plasma
proﬁles between t=0 and the last shared time point for which C > 0
were calculated using the trapezoidal method and correlated.
3. Results
3.1. Comparison of non-radiopaque and radiopaque microspheres
The elution and plasma proﬁles of the non-radiopaque DC Bead
were ﬁrstly compared with the radiopaque DC Bead LUMI, to under-
stand the inﬂuence of bead chemistry on elution rates in the diﬀerent
models with doxorubicin as a representative drug (Fig. 3). The in vitro
models demonstrated that doxorubicin is released from DC Bead LUMI
at a slower rate than from DC Bead, as evidenced by a smaller elution
‘burst’ and Cmax in VFS model, a pattern which was well reﬂected in the
early swine pharmacokinetic proﬁle (Fig. 3A & C). The slow ﬂow
through cell model also showed a diﬀerence between the two bead
types, with the radiopaque beads releasing a lower proportion of the
doxorubicin dose compared with non-radiopaque beads: 40% of the
dose was eluted after 12 days compared with 70% for DC Bead
(Fig. 3B). However, the level of doxorubicin in the plasma declined at a
similar rate for both bead types, reaching low levels (< 1 ng/mL) by
24 h and becoming undetectable by 72 h after administration (Fig. 3D).
3.2. Radiopaque drug-loaded bead characterization and leaching in
contrast agent
Focusing on the radiopaque bead platform, the characteristics of
DEBs loaded with the three diﬀerent drugs were then examined.
Loading of the radiopaque beads with the various drugs under study led
in each case to a DEB formulation consisting of perfectly spherical and
smooth beads with a precisely identiﬁed drug dose and within the
speciﬁed 70–150 μm size range (averages between 90 and 100 μm) as
shown in Fig. 4.
The amount of drug released from radiopaque DEBs during contrast
agent storage over a 24 h period was shown to vary depending on drug
type. The amount of vandetanib released from LUMIVAN into the
contrast medium 15min after mixing was 3.3mg, which increased to
just 3.5mg in total after 24 h storage at room temperature representing
3.5% of the loaded dose. On the other hand, irinotecan was quickly
leached from LUMIRI upon mixing with contrast agent, and the amount
released continued to increase with extended storage, from 1.9% (im-
mediately after mixing) to 10.8% (4 h). LUMIDOX was stable in contrast
agent and eluted only 0.2% of the loaded dose in up to 4 h of storage.
There was no further leaching of irinotecan or doxorubicin after 4 h,
suggesting equilibrium concentrations were achieved for these drugs in
the given volume of contrast agent.
3.3. In vivo pharmacokinetics of radiopaque DEB (swine study)
The pharmacokinetic proﬁles for the three drugs are seen to be
diﬀerent in each case when comparing the curve shapes in Fig. 5(A),
which shows the respective plasma concentrations for each drug over
the ﬁrst 24 h following DEB administration. The Cmax (see also Table 1)
for LUMIRI is much higher than for LUMIDOX and LUMIVAN. LU-
MIDOX reaches Cmax within minutes and declines rapidly, whereas
LUMIRI takes between 1 and 2 h and declines over the next 24 h. LU-
MIVAN shows a relatively low Cmax at about 1 h and persists in the
plasma with a slow decline over several days. Fig. 5(B) provides an
alternative 24 h plot whereby double Y axes are used to allow the LU-
MIRI to be scaled to the same order of magnitude as the other DEBs, and
Fig. 5(C) shows the same data over a 120 h period to demonstrate the
long period over which vandetanib can be detected in the plasma post
administration.
Plotting the log10 of plasma concentrations (Cp) vs time resulted in
diﬀerent slopes for the diﬀerent drugs (Fig. 5(D)). Vandetanib and ir-
inotecan showed a linear relationship between log Cp and time, in-
dicating that the pharmacokinetics of these drugs are best ﬁt by a one-
compartment model. On the other hand, doxorubicin pharmacokinetics
appeared to be more multi-phasic, which suggests a multi-compartment
model may be applicable, as has been previously suggested (Gustafson
et al., 2002; Reich et al., 1979).
3.4. Early phase in vitro drug release (VFS model)
The drug release proﬁle obtained using the VFS elution model re-
presenting the ﬁrst 30min of bead administration is shown in Fig. 6
represented as raw concentration time data (A) and cumulative release
as percentage of the total dose (B). The elution rate peaks within the
ﬁrst 5 min, demonstrating a ‘burst’ eﬀect that is clearly more pro-
nounced with irinotecan than with vandetanib or doxorubicin. The
accumulation of beads in the channel ends led to a dramatic decrease in
eluent ﬂow rate passing through the occlusive bead mass, which cor-
responded with the drop in elution rate. The ﬂow rate proﬁle was si-
milar for each DEB tested. The amount of drug released over 30min
corresponded to approximately 9% of the total dose for irinotecan,
2.6% for doxorubicin and 2.1% for vandetanib.
Fig. 6(C) shows the correlation of the VFS elution data with the ﬁrst
30min of the in vivo plasma pharmacokinetic proﬁles. The AUC of
doxorubicin and irinotecan plasma proﬁles were calculated using the
trapezoidal method, and plotted against cumulative % release from the
VFS elution data at corresponding time points (2, 5, 11, 25min from
start of bead administration). Doxorubicin showed a more linear cor-
relation than irinotecan, but in both cases the data appeared better
ﬁtted by an exponential curve, indicating that drug was released faster
in vitro than in vivo. Tmax for doxorubicin were in a similar timeframe in
vitro and in vivo (t=0.9min vs t=4min respectively). The diﬀerence
was greater for irinotecan, with the VFS showing Tmax to be 2min,
whereas maximal plasma concentrations were seen at approximately
1 h in the swine model. The frequency of blood draws in the vandetanib
bead swine pre-clinical study was not suﬃcient to allow a point-to-
point correlation with VFS data. However, Tmax were compared and
also found to diﬀer signiﬁcantly, with the VFS model showing Tmax at
3min compared with 2 h in vivo. The dose adjusted Cmax values were
not drastically diﬀerent between in vivo and in vitro, indicating that
similar proportions of the drug dose contained within the beads were
released in the early phase set up, albeit at an accelerated time course.
The compared Cmax and Tmax for each drug are summarised in Fig. 6(D).
3.5. Later phase in vitro drug release (open loop ﬂow through model)
Comparison of the later phase release (post formation of an occlu-
sive mass of beads) of the various DEBs as modelled using the open-loop
ﬂow through model is shown in Fig. 7(A) as dose with time (expansion
inset 7(B)), and Fig. 7(C) as cumulative percentage dose released. Using
this method, irinotecan is still seen to release relatively rapidly com-
pared to the other drugs with complete release achieved in around
2 days. Doxorubicin displays a sustained and slow elution, with around
45% of the dose eluted within 16 days and continuing at a slow rate.
Vandetanib displays an intermediate release pattern, with a linear zero
order release phase over the ﬁrst 5 days that plateaus after 90% is
eluted.
Comparing the raw concentration-time data for the ﬂow through
model with the in vivo PK data, we see that the Tmax are fairly similar to
their in vivo counterparts for vandetanib and irinotecan (3 h vs 1 h, 2.2 h
vs 2 h respectively), but the duration of drug release in the model
persists longer than the presence of drug in plasma.
In order to achieve optimal IVIVC, a linear correlation would be
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Fig. 5. Plasma drug concentrations (Cp) over time following administration of 1mL LUMIDOX 37.5mg/mL [red circles] LUMIRI 50mg/mL [blue squares] or
LUMIVAN 100mg/mL [green triangles] in healthy swine liver. A) Cp vs time, 24 h plot. B) Cp vs time with DOX and VAN plotted on left axis, IRI plotted on right axis.
C) Cp vs time as in (B) over 120 h period. D) Log 10 Cp vs time showing linear correlation for LUMIRI (p=0.0003) and LUMIVAN (p < 0.0001). Data are mean of
n≥ 3 animals± SD.
Fig. 6. Drug release data obtained following injection of 0.15mL DEB aliquots using the VFS model, and IVIVC. A) Drug concentration vs time plot demonstrates
early burst release in the ﬁrst 5min. B) Drug release in the VFS as a cumulative percentage of total available dose. C) AUC data from in vivo studies (left axis
LUMIDOX, right axis LUMIRI) is plotted against cumulative % release in VFS for the ﬁrst 30min following DEB delivery to assess IVIVC. LUMIVAN was not plotted
due to lack of comparable time points. D) Comparison of PK parameters derived from in vivo swine studies and VFS model show similarities in dose adjusted Cmax.
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expected between compared parameters over the complete time course.
Interestingly, despite diﬀering by an order of magnitude, when in vitro
and in vivo AUC were plotted against each other, a linear correlation
was achieved for LUMIVAN for the ﬁrst 24 h, but not for LUMIRI or
LUMIDOX (Fig. 8). AUC calculated from the raw concentration time
data from the ﬂow through model correlated better than the convoluted
data in this case, but both ﬁts had an r2 > 0.9. The steep slopes of the
compared AUCs for doxorubicin and irinotecan in the ﬁrst hour is in-
dicative of the drug being observed in the plasma in vivo much faster
than it was observed in the in vitro test (data not shown).
The raw in vitro data from the slow ﬂow through model were con-
voluted using a ﬁrst order elimination model as described in Eq. (1)
(Fig. 9). The convoluted ﬂow through data for LUMIVAN and LUMIRI
showed similarity in curve shape to the plasma proﬁles, predicting a
similar elimination time course for the drugs from the plasma. The
convolution was not extended past 48 h due to the infrequency of
comparable data points beyond this time: the average plasma Tlast for
LUMIRI, LUMIDOX and LUMIVAN were 12 h, 48 h and 72 h respec-
tively. The predicted maximum plasma concentrations as well as AUC
for all DEBs were between 5.2 and 66.3-fold lower than the actual
values, however at later stages (24–48 h) the predicted and actual
concentrations begin to converge. The in vitro Tmax in all cases occurred
several hours later compared with in vivo. For doxorubicin, the con-
voluted elution proﬁle did not correlate well in terms of curve shape
with the actual plasma proﬁle, predicting a much lower Cmax and
slower elimination of the drug. However, from 12 h onwards, the pre-
dicted and actual doxorubicin concentrations are within 1–2 ng/mL of
each other, which may explain why the compared AUCs diﬀered less
than the Cmax values.
4. Discussion
4.1. Eﬀect of drug chemistry on release from DEB
Drug release from the DEBs used in this study is based on ion ex-
change (Lewis, 2009). Upon contact with biological ﬂuids, small cations
exchange with the positively charged drug molecules in the micro-
sphere matrix. The rate controlling mechanisms for diﬀerent drugs, for
example doxorubicin and irinotecan, have been found to vary based on
diﬀering molecular interactions between drug and bead (Biondi et al.,
2013), which explains diﬀerences in release rates observed both in vitro
and in vivo. Doxorubicin binds via a primary amine group, which is
expected to interact more strongly with the beads than irinotecan's
tertiary amine, and also exhibits pi-pi stacking which could be a cause
of drug aggregation within the bead leading to slow elution (Ahnfelt
et al., 2016). Indeed, a high propensity to form aggregates has been
correlated with slower release rates of amphiphilic substances from
DEBs (Ahnfelt et al., 2018). Vandetanib possesses two potential ionic
binding sites dependent on the pH and subsequent protonation state of
the molecule (see Fig. 4): at pH 7, only the tertiary amine is protonated,
whilst at loading pH (4.6–4.8) 30–40% of molecules are expected to
carry an additional positive charge in the pyrimidine group. We have
previously described how this property aﬀects the vandetanib loading
capacity into DEB due to occupation of multiple binding sites per mo-
lecule, however it does not signiﬁcantly aﬀect the drug release rate of
beads loaded at diﬀerent pH due to partial charge neutralisation in the
pH 7 PBS elution medium (Hagan et al., 2017). It does however, explain
why vandetanib is released more quickly from the open-loop ﬂow-
through method than expected based on solubility of the free-base
alone, as the protonated form is released from the bead and remains
partially protonated and hence more soluble within the PBS. In the
models employed in this study, vandetanib was released from DEBs
more slowly than irinotecan, but faster than doxorubicin, suggesting it
forms weaker drug – bead interactions than the latter and/or lacks the
drug-drug interactions that exist for doxorubicin. This resulted in the
complete release of vandetanib from DEB in the ﬂow through model
after ~10 days, whereas complete doxorubicin release was not achieved
after 2 weeks. This is in line with a previous in vivo study, where<50%
of the doxorubicin dose contained with DC Beads was found to be re-
leased 28 days after implantation in swine liver (Namur et al., 2010).
The chemistry of the bead matrix also plays a role in drug release
rates, as has been previously demonstrated in comparison of DC Bead
and the radiopaque DC Bead LUMI (Hagan et al., 2017; Ashraﬁ et al.,
2017). Despite the drug binding mechanism being theoretically un-
altered, the matrix is rendered more hydrophobic and dense by the
addition of the radiopaque moiety, reducing the size of the water-ﬁlled
channels in the hydrogel matrix and impeding transport of drug mo-
lecules within the beads. This led to a slower drug release in vitro and a
lower plasma Cmax in the swine pharmacokinetic study, which suggests
a reduced systemic exposure to the drug. However, it has not yet been
determined whether this diﬀerence is signiﬁcant enough to translate
into clinically meaningful diﬀerences in systemic toxicity.
Fig. 7. Drug release proﬁles obtained using the ﬂow through cell model. A)
Raw concentration time data, B) (inset) expanded view of the ﬁrst 6 days. C)
Data plotted as cumulative release as percentage of total dose.
Fig. 8. Assessment of IVIVC between in vitro and in vivo AUC from raw
LUMIVAN ﬂow through elution data. Linear correlation was achieved for the
ﬁrst 24 h (p < 0.0001). Later time points (72 h and 168 h) were excluded from
the linear regression analysis.
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4.2. Evaluation of the in vitro elution models
4.2.1. VFS model
The VFS model allows the reproduction of many phenomena ex-
perienced during administration of DEB in the clinic: suspension in
contrast agent, gradual (rather than instantaneous) DEB delivery, ex-
posure to high rate pulsatile ﬂow of elution medium, and eventual
packing of beads in a conﬁned channel. The presence of these features is
a vast improvement in representativeness of the in vivo situation, in
comparison to the basic USP type set-ups. This may have been key to
having achieved correlation of the elution data with the ﬁrst 30min of
in vivo plasma concentration data in the case of doxorubicin release
from both DEB platforms. For LUMIRI and LUMIVAN the model pre-
dicted an earlier Tmax than the in vivo value. However, the dose adjusted
Cmax were in a similar range to the in vivo values for all three drugs,
suggesting that the model may be useful in predicting the extent of
burst release in comparison with other drugs. The accelerated release
time course observed in the VFS may simply be a function of the con-
densed nature of the model. The volume of bead suspension delivered is
a tenth of what is used in the swine model, therefore delivery of the
entire dose does not take as long, and the channels are blocked quickly
as beads reach the ﬁlters, leading to the reduction of drug release.
Another key diﬀerence is that since the VFS is a semi-open loop system,
the drug concentration that is recorded at each time point provides a
snapshot of what has been released in that moment, in other words the
drug does not have the opportunity to accumulate as it would in the
plasma prior to the start of elimination. Doxorubicin has a very short
distribution half-life of 5min (Drugbank, 2017), in other words it is
quickly distributed into other bodily compartments which is reﬂected in
its early disappearance from the plasma compared to irinotecan and
vandetanib. This may be why a better correlation was achieved with
doxorubicin in the VFS, where the eluted drug is also quickly removed
from the system.
4.2.2. Flow through model
The ﬂow through cell model employed in this study mimics packing
of beads in blood vessels with a very slow ﬂow rate, which makes it
suitable for modelling the mid to late phase of drug release from DEB
i.e. post-administration. A number of other drug elution methods have
been described in the literature that attempt to model drug release over
this phase, including a T-apparatus in which DEBs sit in a well and drug
release controlled initially by diﬀusion in the well followed by more
distant convection (Amyot et al., 2002). More recently, a USP Type IV
ﬂow-through system was described in which DEBs were placed on top
of a column of glass beads that generate a laminar ﬂow regime (Jordan
et al., 2010). Each of these methods has its merits but also limitations in
terms of practical use and by no means reﬂect the actual elution kinetics
observed in vivo. The ﬂow through system was capable of distinguishing
between the three drug types, showing the same pattern as the in vivo
data in terms of the relative release rate of irinotecan, vandetanib and
doxorubicin as a consequence of drug binding strength, interactions,
and solubility. A linear point-to-point correlation was achieved for the
ﬁrst 24 h when comparing the AUC derived from the ﬂow through data
and in vivo plasma data for vandetanib. The lack of correlation after
24 h was caused by the drug levels dropping signiﬁcantly in the swine
plasma whilst drug release in vitro continued. This is likely due to the
onset of phase 3 drug release in vivo, where blood clotting and stasis has
occurred and the beads are ﬁrmly embedded in an embolus. Drug dif-
fuses out of the beads and now directly into the surrounding tissue,
rather than directly into the blood circulation as can occur during the
administration and redistribution phases. The presence of plasma pro-
teins in blood may also contribute to diﬀerences in drug release rate in
vivo, as adsorption of these proteins into PVA based biomaterials has
been documented with unknown eﬀects on drug release. The in vitro
elution system therefore is not reﬁned enough to be able to model this
biological process. Doxorubicin and irinotecan had diﬀerential release
rates in the ﬂow through model compared to in vivo, and a point to
point IVIVC was not even achieved for these drugs.
By convoluting in vitro elution data, it is possible to predict plasma
concentrations by mathematical simulation of drug elimination. When
this process was applied to our data, the convoluted in vitro proﬁles only
showed similarities in elimination phase curve shape for vandetanib
and irinotecan. In contrast to the VFS model, the predicted Tmax were
this time several hours later than the actual in vivo Tmax. However, this
Fig. 9. Convoluted ﬂow through cell elution data (top row) compared with in vivo plasma concentration (bottom row) for A) LUMIVAN, B) LUMIRI and C) LUMIDOX
and comparison of in vitro and in vivo PK parameters (tables inset).
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can be explained by the fact that the ﬂow through elution process is
started with the beads already in an occlusive mass, therefore the burst
eﬀect is not modelled and the drug will take longer to reach a peak
concentration. FDA guidance states that time-scaling or time shift cor-
rection may be applied to the in vitro proﬁle to improve the alignment
(FDA, 1997), which has been successfully implemented in developing
IVIVC in non-intravenous microsphere formulations using modiﬁed
USP IV apparatus (Andhariya et al., 2017). Doxorubicin IVIVC was not
improved by implementing a simple time shift correction to account for
the slow initial release rate, therefore further investigation is required
to establish if time-scaling may be appropriate. If the time-scaling factor
is found to be non-linear, the lack of consistency between release rates
should be treated as a limitation of the in vitro model.
Despite using the same volume of beads and drug doses as were used
in the in vivo studies, the convoluted proﬁle signiﬁcantly under-
estimated the plasma concentrations of all three drugs, although the
disparity decreases over time and the values begin to converge after
24 h–48 h. Again, this may be related to the lack of the burst phase and
the tight packing and slow ﬂow rate of the system. In particular, dox-
orubicin was initially very slow to elute from the beads in the ﬂow
through model, which may be due to how it is released when packed in
a column. Swaine et al. (2016) found that dox release from DC Bead™ in
a column was based on a process of drug desorption from the near end
of the column, followed by resorption by beads further along in the
direction of ﬂow (Swaine et al., 2016). This results in the beads furthest
away from the ﬂow source becoming loaded with more drug than the
initial loading dose, which may increase drug aggregation and impede
ion inﬂux. This eﬀect has resulted in a slow, sustained release of dox in
the ﬂow through model, which oﬀset the simulated elimination giving a
shallower elimination curve in the convoluted data. In vivo, as pre-
viously mentioned dox is quickly distributed into tissues and this is not
accounted for in the convolution process.
Convolution of in vitro data is one approach to develop an IVIVC,
however the method used in this study is traditionally used for either
oral or instantaneous i.v. dosage forms, which may mean it is not op-
timised for controlled release applications. Indeed, a further limitation
of our pharmacokinetic studies was restriction of the number of blood
samples that could be taken and hence lack of data points for correla-
tion. Reported T1/2 and Vd for the drugs were found to be variable in the
literature, and values obtained for humans may not be applicable to
swine. Therefore, apparent T1/2 and Vd were obtained from the corre-
sponding DEB pre-clinical studies where possible to improve accuracy.
For LUMIDOX they could not be calculated and therefore the para-
meters were taken from a published study that used i.v. infusion of dox
solution in swine rather than DEB, which may limit the accuracy of the
prediction, as controlled release formulations can cause apparent T1/2
and Vd to vary from the standard values. A possible alternative ap-
proach would be to de-convolute the in vivo data and compare this with
the dissolution proﬁles.
5. Conclusions
The models described here have given an insight into how we may
start to improve representativeness of in vitro elution testing for drug
eluting beads. The early phase VFS model allowed an estimation of the
proportion of drug that would be released during the administration
phase of DEB-TACE, which can provide an indicator of the relative
degree of systemic exposure for diﬀerent drugs. Vandetanib burst re-
lease from LUMIVAN was within a similar range to commonly used
drugs irinotecan and doxorubicin, therefore providing encouragement
that systemic exposure will remain within acceptably low levels for this
novel DEB. The ﬂow through model, as intended, seemed more suited to
modelling mid to late phase drug release as it did not predict the early
burst eﬀect, but instead corresponded better to the drug elimination
phase. It seems that adapting and combining these two methods may
oﬀer an improved method of predicting plasma drug concentrations
after DEB treatment. Looking forward, it will be of interest to develop a
third model based on drug diﬀusion from DEB into a biomimetic matrix
in order to model tissue diﬀusion, which will complete the picture of
the fate of drugs released from embolic beads.
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